Insmed has received approval from the EC for Brinsupri to treat NCFB in patients aged 12 and above with two or more ...

At two upcoming events, experts will offer practical solutions to key challenges for oncology and rare disease clinical ...

Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of ...

In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.